Nabriva Therapeutics set to double on pneumonia drug trial success

Share

Nabriva Therapeutics. Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia.

As such, the analyst reiterates an Overweight rating on shares of NBRV with a $16 price target, which implies a just under 62% upside from where the stock is now trading. It indicates oversold and overbought price levels for a stock.

Taking a closer look into the volatility on shares of Nabriva Therapeutics plc (NASDAQ:NBRV), we notice that the stock is 13.91% off of the 20-Day Simple Moving Average. It is quantified by short-term traders as the average difference between a stock's daily high and daily low, then divided by the stock price.

Analysts expect First Data Corporation (NYSE:FDC) to report $ 0.40 EPS and has got OUTPERFORM rating from 11 of Thomson Reuters analysts and 0 analyst (s) given UNDERPERFORM rating. The original version of this report can be viewed at https://www.truebluetribune.com/2017/09/19/nabriva-therapeutics-ag-nbrv-price-target-increased-to-24-00-by-analysts-at-suntrust-banks-inc.html. Cantor Fitzgerald started coverage on shares of Nabriva Therapeutics AG in a report on Thursday, June 22nd. This represents a change from most recent open price of 10.49%. The firm's 50 day moving average is $9.05 and its 200 day moving average is $10.21.

The share price of the company (NASDAQ:NBRV) was up +29.30% during the last trading session, with a high of 14.10 and the volume of Nabriva Therapeutics AG shares traded was 17492542. Company fiscal year is ending in December and analysts' consensus recommendation is Hold for DNKN and estimated EPS for next quarter is $ 0.63. The value of the investment in Nabriva Therapeutics plc - Ordi increased from $4,210,000 to $8,133,000 a change of $3,923,000 for the reporting period.

A number of large investors have recently modified their holdings of NBRV. 1 equities equity analyst has recommended the share with a sell recommendation, 1 have issued a hold recommendation and around seven have published a buy recommendation to the share. - Ordinary Shares (NASDAQ:NBRV) has commenced a public offering of its ordinary shares valued at $80 million. After this sale, 2,370,735 common shares of NBRV are directly owned by the insider, with total stake valued at $21,028,419. Finally, Wellington Management Group LLP lifted its position in shares of Nabriva Therapeutics AG by 9.9% during the first quarter.

Nabriva's treatment belongs to a new class of antibiotics called pleuromutilins, which inhibit bacterial growth by binding to a specific site on the bacterial ribosome that is responsible for its protein synthesis.

However, investors should remember that Nabriva is far from the only company with a dog in this race. Shares of the clinical-stage biotech are up 15% as of 11:30 a.m. EDT on Tuesday. The Company's medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Share